BMS-986393, a novel anti-GPRC5D CAR-T cell therapy, in multiple myeloma

BMS-986393: GPRC5D-targeted CAR for R/R myelomaПодробнее

BMS-986393 CAR T-cell therapy for R/R multiple myeloma: results of a Phase I trialПодробнее

GPRC5D Directed CAR T-Cell Therapy | University of Alabama | Susan Bal, MD | ASH 2023Подробнее

Updates on the QUINTESSENTIAL trial: second-generation anti-GPRC5D CAR-T in myelomaПодробнее

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMMПодробнее

GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)Подробнее

An update on the Phase I trial of BMS-986393, a novel GPRC5D-targeted CAR-T, in R/R myelomaПодробнее

Updated safety and efficacy of BMS-986393 in patients with R/R myeloma and 1-3 prior LOTПодробнее

Promise of GPRC5D-targeted CAR-T therapies in multiple myelomaПодробнее

What is CAR T-cell therapy and how does it work?Подробнее

CAR T-Cell Therapy For Multiple Myeloma - Michael's Story - Nebraska MedicineПодробнее

CAR-T therapy in multiple myeloma: recent updates, clinical trials and future outlooksПодробнее

CAR T-CELL Therapy in Multiple Myeloma, When & How Effective - Dr. Jesus Berdeja(Sep 30-Oct 1, 2022)Подробнее

Q&A | How to sequence CAR T-cell therapy and bispecific antibodies in R/R MMПодробнее

CAR T Cell Therapy in China for Multiple Myeloma - Bjorn Simensen Story at Bioocus BiotechПодробнее

Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023Подробнее

Management of multiple myeloma during CAR-T therapy manufacturingПодробнее

A New Target for CAR-T Therapy in Myeloma - GPRC5D | Fredrik Schjesvold, MD | ASH 2021Подробнее

CAR T Cell Therapy in China for Multiple Myeloma - Nergui Story at Bioocus BiotechПодробнее